MNG991
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG318 | — | — | 0.856 |
| 2 | SRR10900571 | — | — | 0.856 |
| 3 | 20030005.Her2HRpos | — | A | 0.852 |
| 4 | TCGA-BH-A1EU-01A-11R-A137-07 | — | A | 0.851 |
| 5 | MNG708 | — | — | 0.840 |
| 6 | SRR8613773 | — | A | 0.834 |
| 7 | BS_CS170P7T | pilocytic astrocytoma | — | 0.833 |
| 8 | TCGA-A2-A0YK-01A-22R-A109-07 | — | A | 0.829 |
| 9 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.828 |
| 10 | SRR8613789 | — | A | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.482 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.446 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.365 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.343 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.254 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.238 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.232 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.198 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.173 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.159 | Inavolisib | — uncovered |
| COMPLEMENT | 0.152 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.151 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.139 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.117 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.091 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.072 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.053 | Inavolisib | — uncovered |